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>50 years (P ¼ .56). Patients with DCB transplant had 63%
infections vs. 31% in the other transplant types (P ¼ .059).
Gram-positive cocci were isolated in 57% and Gram-negative
rods in 26% of all infections. DVT occurred in 26% of all cases.
DVT rates according to the presence or absence of a particular
catheter type were 27% vs. 25% for Hickman, 37% vs. 17% for
PICC (P ¼ .1) and 14% vs. 29% for IP (P ¼ .6). In patients with
only one catheter type, DVT rates were 17% for Hickman vs.
25% for PICC (P¼ .4). DVToccurred in 18% of patients 50 years
of age or younger and in 47% of those >50 years (P ¼ .026).
Conclusion: Among AML patients who underwent HSCT at
our institution, we did not observe any signiﬁcant differences
in catheter-related complications according to catheter type.
DVT rate was signiﬁcantly higher in patients older than 50
years. There was a trend of higher infection rate with double
cord blood transplant compared to other transplant types.309
Suicidal Protocol in Blood and Marrow Outpatient
Transplant Setting
Denise Kramer. Bone Marrow Transplant, Texas Oncology,
Dallas, TX
This information is intended to give background and inter-
vention options for healthcare professionals in the transplant
outpatient setting dealing with patients that are at risk for
suicide.
In 2007, there were 34,598 deaths by suicide in the United
States. Suicide is the fourth leading cause of death in adults,
ages 18 to 65 years. According to the Annals of Oncology
persons diagnosed with cancer have double the risk of
committing suicide compared to the general population.
It is important to identify those patients who are at greatest
risk of suicide. Symptoms of suicidal ideation include feelings
of hopelessness, anhedonia, insomnia, depression, severe
anxiety, impaired concentration, psychomotor agitation,
panic attack, and severe remorse. The Health Care Provider
needs to establish an atmosphere of trust to encourage the
patient to express their current symptoms. There are tools
available for health care providers in outpatient clinics that
can provide the ability to calculate the patient's risk. Some of
those tools include but are not limited to the Beck Scale, BSI
18, and SAFE T.
This program has experienced loss due to suicide in the past
several years. The program subsequently developed a suicide
protocol to help identify those patients at greatest risk for
suicide. The entire staff was trained on suicidal ideations and
at risk behaviors. When the staff identiﬁes a potential suicide
risk the team is called and further evaluation is completed.
The suicide protocol team consists of a nurse and social
worker. The process is explained to the patient and caregiver.
The nursemanager and the patient's physician are notiﬁed of
the situation. A family member or another staff member stay
with the patient at all times to maintain a safe environment.
We have identiﬁed a crisis team with a nearby psychiatric
facility that will provide further evaluation and recommend
a plan, if the patient is determined to be at risk for suicide. If
the patient appears safe to return home the patient and
family are instructed how tomake the home safe. The patient
will receive a follow up phone call and continued
monitoring.
Since the initiation of this protocol the facility has not had
a suicide attempt or completion.310
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Background: Radiation dermatitis is a frequent complication
following TBI based preparative regimens. There is no
consistent approach to the diagnosis and management of
radiation dermatitis. Many of the topical therapies have side
effects such as skin discoloration and discomfort in the case
of silver sulfadiazine. Newer silver containing agents such as
Silvasorb gel, Melgisorb Ag and Mepilex Ag may facilitate
healing and increase patient comfort.
Objective: To develop a consistent approach to diagnosis and
management of radiation dermatitis and to assess the clinical
outcomes in a pilot study.
Patients: From 2010 to 2012 thirteen patients who under-
went allogeneic BMT following a preparative regimen con-
sisting of 1200 cGy fractionated TBI and Cytoxan (60 mg/kg/
day x 2 days) were evaluated. All patients received daily
topical treatment with a moisturizing barrier cream (Aqua-
phor). Patients were evaluated daily for dermatitis. Radiation
dermatitis was graded according to CTCAE (version 3). Five
patients developed radiation dermatitis between days 0 to 2
post transplant.
Treatment and Results: All of the patients were treated
according to a previously developed algorithm. Two patients
with Grade 2 dermatitis were treated with Silvasorb gel
applied twice daily and reinforced with Xeroform gauze. The
skin lesions did not progress and was restored by day 5.
Three patients who progressed to Grade 3 dermatitis were
initially treated with Silvasorb gel, and the treatment was
changed to Melgisorb (ag) or Mepilex (ag). None of the
patients progressed to Grade 4. The skin lesions in all 3
patients with Grade 3 dermatitis was restored by Day 10 post
transplant and the therapy was discontinued.
Conclusions:
 CTCAE version 3 for assessing dermatitis represents
a useful and consistent tool for deﬁning radiation
dermatitis and allows for early intervention.
 The newer silver containing agents are well tolerated
and in this small series, effective in promoting healing.
 Based on our results an algorithm for early diagnosis
and treatment of grade 2-3 radiation dermatitis was
established.311
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Over the past decade there has been substantial increase in
the available antifungal agents for prevention and treatment
of fungal infections. In parallel with this change, transplant
strategies have become more immunosuppressive and less
myelo-suppressive. In light of these two dynamic changes,
true current incidence and outcome of fungal infections in
patients undergoing HCT remain unknown. To address this,
we evaluated incidence and outcome of fungal infections in
patients undergoing HCT in a large pediatric transplant
center with the focus on reduced intensity conditioning (RIC)
transplant, from January 2004-July 2012.
Forty two patients, 30 with non-malignant disease, and 12
with malignant disease were identiﬁed to have proven
fungal infection and reviewed retrospectively. Donor source
was unrelated donor in 35 (83.3%) and matched related in 7
(16.6%). Stem cell source was bone marrow in 31 (73.8%),
peripheral blood stem cells in 7 (16.6%) and cord blood in 4
(9.5%). Thirteen (31%) patients received alemtuzumab and 21
(50%) received antithymocyte globulin (ATG) as part of
conditioning. Fungal infection was deﬁned as a positive
fungal culture in blood or in body ﬂuids or relevant tissue.
In our cohort, highest number of fungal infections was
caused by Candida albicans, followed by Candida glabrata and
Aspergillus species. Table 1 describes the results in detail.
Thirty one (75%) patients had a history of acute (50%) or
chronic GVHD (25%) requiring use of additional immuno-
suppressive therapy. Infection with mold was uncommon in
patients without GVHD. However, there was no difference in
distribution of infection with yeast vs molds in deceased
patients with h/o GVHD. Overall survival for patients with
proven fungal infection was low at 33%. Fungal infection was
attributed to be the cause of death in almost half of the
deceased patients (13/28 patients - 46%).
In our cohort, the overall incidence of culture proven fungal
infection, distribution of different fungal infections, and
patient outcomes are similar to previous reports. Patients
with h/o GVHD and associated immune suppression appear
to be at a higher risk of developing infections with molds
compared to patients without GVHD, where yeast remain
almost an exclusive offender.Table 1
Fungal Infections in pediatric patients undergoing HSCT
Characteristics Number (range/%)
Total number of patients 42
Age in years 11.33 ( 0.52 -28.67)
Proven fungal infections 57
Median post-HSCT day of fungal detection (range) 91.5 (2-2733)
Type of infection
Fungemia only 15
Yeast 12
Mold 3
Invasive infection with organ involvement 27
Yeast 15
Mold 12
Conditioning regimen
MAC 23 (55%)
RIC 18 (43%)
No conditioning 1 (2%)
Patients with GVHD with fungal infection
Total 31/42 (74%)
Acute GVHD 21 (50%)
Chronic GVHD 10 (25%)
Overall outcome
Alive 14 (33%)
Deceased 28 (67%)
Patients deceased due to fungal infection 13/28 (46%)
MAC e Myeloablative conditioning312
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Allogeneic hematopoietic cell transplantation (alloHCT)
recipients are at an increased for Pneumocystis jirovecii
pneumonia (PCP) post-HCT. Current recommendations for
alloHCT recipients includes a prophylactic regimen until at
least six months post alloHCT or longer in patients receiving
immune suppresive therapy (Tomblyn, BBMT 2009). The
Infectious Disease Society of America guidelines recommend
PCP prophylaxis continue in patients with HIV/AIDS until
CD4+ counts are > 200/uL for more than 3 months. To assess
duration of prophylaxis needed, we retrospectively evalu-
ated 100 patients who received alloHCT for myeloid malig-
nances between 2006 and 2011. Incidence of PCP infection
and toxicity to prophylactic regimen were also evaluated.
Characteristics of the 100 patients are shown (Table 1). 66
patients received systemic steroids post-transplant and 26
patients received anti-thymocyte globulin (ATG) during
conditioning. Primary PCP prophylaxis consisted of trimeth-
oprim-sulfamethoxazole (TMP/SMX) (91%) or pentamadine
(9%). Toxicity to ﬁrst-line therapy did not occur in 61% of
patients and for 7% of patients' toxicity status was unknown.
Toxicity from TMP/SMXoccurred in 32% of patients including
hematologic (78%), dermatologic 6.3%, renal 3.1%, gastroin-
testinal 3.1%, and drug interaction 3.1%. At last contact 36% of
patients had PCP prophylaxis discontinued with CD4+ count
evaluated in 26 patients. At discontinuation in these patients,
the mean CD4+ count was 411/ uL and only 5 patients had
a CD4+ count < 200/uL. Median duration of PCP prophylaxis
was 327 (26-2175) days in all patients evaluated, 369 (38-
2175) days if alive at date of last contact (DLC) (n¼55), 408
(141-2150) days in patients who completed prophylaxis and
were alive at DLC, and 425 (127-2175) days if alive at DLC after
receiving ATG (n¼15). Median time to TMP/SMX toxicity was
Table 1
Variables N ¼ 100
Age at transplant, years, median (range) 51.8 (22-74)
Gender
Male 51
Female 49
Primary Diagnosis
AML 61
CML 5
MDS 29
MPS 4
MYF 1
Received Systemic steroids
Yes 66
No 34
Received ATG
Yes 26
No 74
Conditioning Intensity
Myeloablative 92
Reduced intensity/non-myeloablative 8
Donor Type
Matched related 33
Matched unrelated 38
Mismatched related 2
Mismatched unrelated 25
Umbilical cord blood 2
